| 摘要 |
Provided are methods for treating prostate cancer using TOR kinase (mTOR) inhibitors. Further provided are methods of determining the response of prostate cancers to TOR kinase inhibitors by measuring the phosphorylation of S6RP, 4E-BP1, AKT or DNA-PK. In an embodiment the TOR kinase inhibitor is a compound of formula (IV), where the variables are as defined in the specification, such as 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one . |
